Interactions between gut inflammation and arthritis/spondylitis

Current Opinion in Rheumatology

Volumn 22, Issue 4, 2010, Pages 368-374

  Jacques, Peggy ^a   Elewaut, Dirk ^a   Mielants, Herman ^a  

^a GHENT UNIVERSITY HOSPITAL   (Belgium)

Author keywords

Interleukin 23 receptor; Spondyloarthritis; Tumor necrosis factor

Indexed keywords

ADALIMUMAB; BETA 2 MICROGLOBULIN; CASPASE RECRUITMENT DOMAIN PROTEIN 15; CD163 ANTIGEN; ETANERCEPT; HLA B27 ANTIGEN; INFLIXIMAB; INTERLEUKIN 17; INTERLEUKIN 23; INTERLEUKIN 23 RECEPTOR; MACROPHAGE INFLAMMATORY PROTEIN 3ALPHA; MAJOR HISTOCOMPATIBILITY ANTIGEN; PLACEBO; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR INHIBITOR; TUMOR NECROSIS FACTOR RECEPTOR;

ADAPTIVE IMMUNITY; ANKYLOSING SPONDYLITIS; CLINICAL TRIAL; CROHN DISEASE; DIGESTIVE SYSTEM INFLAMMATION; DISEASE MODEL; GENE LOCUS; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC LINKAGE; GENETIC POLYMORPHISM; GENETIC PREDISPOSITION; GENETIC SUSCEPTIBILITY; HUMAN; INNATE IMMUNITY; MEDICAL RESEARCH; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; STROMA CELL;

ANIMALS; ARTHRITIS; HUMANS; INFLAMMATION; RECEPTORS, INTERLEUKIN; SPONDYLITIS; STOMACH DISEASES;

EID: 77953478395     PISSN: 10408711     EISSN: None     Source Type: Journal    
DOI: 10.1097/BOR.0b013e3283393807     Document Type: Review

References (86)

1. Leirisalo-Repo M. Prognosis, course of disease, and treatment of the spon-dyloarthropathies. Rheum Dis Clin North Am 1998; 24:737-751; viii.
2. Cuvelier C, Barbatis C, Mielants H, et al. Histopathology of intestinal inflammation related to reactive arthritis. Gut 1987; 28:394-401.
3. De Vos M, Cuvelier C, Mielants H, et al. Ileocolonoscopy in seronegative spondylarthropathy. Gastroenterology 1989; 96 (2 Pt 1):339-344.
4. Mielants H, Veys EM, Cuvelier C, et al. HLA-B27 related arthritis and bowel inflammation. Part 2. Ileocolonoscopy and bowel histology in patients with HLA-B27 related arthritis. J Rheumatol 1985; 12:294-298. (Pubitemid 15025372)
5. Mielants H, Veys EM, Joos R, et al. Repeat ileocolonoscopy in reactive arthritis. J Rheumatol 1987; 14:456-458.
6. Mielants H, Veys EM, De Vos M, et al. The evolution of spondyloarthropathies in relation to gut histology. I. Clinical aspects. J Rheumatol 1995; 22:2266-2272.
7. Mielants H, Veys EM, Cuvelier C, et al. The evolution of spondyloarthropathies in relation to gut histology. III. Relation between gut and joint. J Rheumatol 1995; 22:2279-2284.
8. Mielants H, Veys EM, Cuvelier C, et al. The evolution of spondyloarthropathies in relation to gut histology. II. Histological aspects. J Rheumatol 1995; 22:2273-2278.
9. Leirisalo-Repo M, Turunen U, Stenman S, et al. High frequency of silent inflammatory bowel disease in spondylarthropathy. Arthritis Rheum 1994; 37:23-31.
10. Mielants H, Veys EM, Cuvelier C, de Vos M. Ileocolonoscopic findings in seronegative spondylarthropathies. Br J Rheumatol 1988; 27 ((Suppl 2)):95-105.
11. Brewerton DA, Hart FD, Nicholls A, et al. Ankylosing spondylitis and HL-A 27. Lancet 1973; 1:904-907.
12. Palm O, Moum B, Ongre A, Gran JT. Prevalence of ankylosing spondylitis and other spondyloarthropathies among patients with inflammatory bowel disease: a population study (the IBSEN study). J Rheumatol 2002; 29:511-515.
13. Purrmann J, Zeidler H, Bertrams J, et al. HLA antigens in ankylosing spondylitis associated with Crohn's disease. Increased frequency of the HLA phenotype B27, B44. J Rheumatol 1988; 15:1658-1661.
14. Steer S, Jones H, Hibbert J, et al. Low back pain, sacroiliitis, and the relationship with HLA-B27 in Crohn's disease. J Rheumatol 2003; 30:518-522.
15. Burton PR, Clayton DG, Cardon LR, et al. Association scan of 14500 nonsynonymous SNPs in four diseases identifies autoimmunity variants. Nat Genet 2007; 39:1329-1337.
16. Duerr RH, Taylor KD, Brant SR, et al. A genome-wide association study identifies IL23R as an inflammatory bowel disease gene. Science 2006; 314:1461-1463.
17. Rahman P, Inman RD, Gladman DD, et al. Association of interleukin-23 receptor variants with ankylosing spondylitis. Arthritis Rheum 2008; 58:1020-1025.
18. Hammer RE, Maika SD, Richardson JA, et al. Spontaneous inflammatory disease in transgenic rats expressing HLA-B27 and human beta 2m: an animal model of HLA-B27-associated human disorders. Cell 1990; 63:1099-1112.
19. Taurog JD, Richardson JA, Croft JT, et al. The germfree state prevents development of gut and joint inflammatory disease in HLA-B27 transgenic rats. J Exp Med 1994; 180:2359-2364.
20. Breban M, Fernandez-Sueiro JL, Richardson JA, et al. T cells, but not thymic exposure to HLA-B27, are required for the inflammatory disease of HLA-B27 transgenic rats. J Immunol 1996; 156:794-803.
21. Kontoyiannis D, Pasparakis M, Pizarro TT, et al. Impaired on/off regulation of TNF biosynthesis in mice lacking TNF AU-rich elements: implications for joint and gut-associated immunopathologies. Immunity 1999; 10:387-398.
22. Armaka M, Apostolaki M, Jacques P, et al. Mesenchymal cell targeting by TNF as a common pathogenic principle in chronic inflammatory joint and intestinal diseases. J Exp Med 2008; 205:331-337.
23. Kontoyiannis D, Boulougouris G, Manoloukos M, et al. Genetic dissection of the cellular pathways and signaling mechanisms in modeled tumor necrosis factor-induced Crohn's-like inflammatory bowel disease. J Exp Med 2002; 196:1563-1574.
24. de Vlam K, Mielants H, Cuvelier C, et al. Spondyloarthropathy is underestimated in inflammatory bowel disease: prevalence and HLA association. J Rheumatol 2000; 27:2860-2865.
25. Schroder M, Kaufman RJ. ER stress and the unfolded protein response. Mutat Res 2005; 569 (1-2):29-63.
26. Tran TM, Dorris ML, Satumtira N, et al. Additional human beta2-microglobulin curbs HLA-B27 misfolding and promotes arthritis and spondylitis without colitis in male HLA-B27-transgenic rats. Arthritis Rheum 2006; 54:1317-1327.
27. Reveille JD. Major histocompatibility genes and ankylosing spondylitis. Best Pract Res Clin Rheumatol 2006; 20:601-609.
28. HisamatsuT, Suzuki M, Reinecker HC, et al. CARD15/NOD2 functions as an antibacterial factor in human intestinal epithelial cells. Gastroenterology 2003; 124:993-1000.
29. Lala S, Ogura Y, Osborne C, et al. Crohn's disease and the NOD2 gene: a role for paneth cells. Gastroenterology 2003; 125:47-57.
30. Ogura Y, Inohara N, Benito A, et al. Nod2, a Nod1/Apaf-1 family member that is restricted to monocytes and activates NF-kappaB. J Biol Chem 2001; 276:4812-4818.
31. Ogura Y, Lala S, Xin W, et al. Expression of NOD2 in Paneth cells: a possible link to Crohn's ileitis. Gut 2003; 52:1591-1597. (Pubitemid 37363443)
32. Rosenstiel P, Fantini M, Brautigam K, et al. TNF-alpha and IFN-gamma regulate the expression of the NOD2 (CARD15) gene in human intestinal epithelial cells. Gastroenterology 2003; 124:1001-1009.
33. van Beelen AJ, Zelinkova Z, Taanman-Kueter EW, et al. Stimulation of the intracellular bacterial sensor NOD2 programs dendritic cells to promote interleukin-17 production in human memory T cells. Immunity 2007; 27:660-669.
34. Hampe J, Cuthbert A, Croucher PJ, et al. Association between insertion mutation in NOD2 gene and Crohn's disease in German and British populations. Lancet 2001; 357:1925-1928.
35. Hugot JP, Chamaillard M, Zouali H, et al. Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease. Nature 2001; 411:599-603.
36. Ogura Y, Bonen DK, Inohara N, et al. A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease. Nature 2001; 411:603-606.
37. Crane AM, Bradbury L, van Heel DA, et al. Role of NOD2 variants in spondylarthritis. Arthritis Rheum 2002; 46:1629-1633.
38. Laukens D, Peeters H, Marichal D, et al. CARD15 gene polymorphisms in patients with spondyloarthropathies identify a specific phenotype previously related to Crohn's disease. Ann Rheum Dis 2005; 64:930-935.
39. Miceli-Richard C, Zouali H, Lesage S, et al. CARD15/NOD2 analyses in spondylarthropathy. Arthritis Rheum 2002; 46:1405-1406.
40. Laukens D, Peeters H, Cruyssen BV, et al. Altered gut transcriptome in spondyloarthropathy. Ann Rheum Dis 2006; 65:1293-1300.
41. Wiekowski MT, Leach MW, Evans EW, et al. Ubiquitous transgenic expression of the IL-23 subunit p19 induces multiorgan inflammation, runting, infertility, and premature death. J Immunol 2001; 166:7563-7570.
42. Peyrin-Biroulet L, Parmentier-Decrucq E, Branche J, Desreumaux P. IL-23R, a novel susceptibility gene for inflammatory bowel disease. Med Sci (Paris) 2007; 23:250-252.
43. Capon F, Di Meglio P, Szaub J, Prescott NJ, Dunster C, Baumber L, et al. Sequence variants in the genes for the interleukin-23 receptor (IL23R) and its ligand (IL12B) confer protection against psoriasis. Hum Genet 2007; 122: 201-206.
44. Reveille JD. ea. IL-23R is a major determinant of ankylosing spondylitis risk-the TASC study. Annals of the Rheumatic Diseases 2007; 66 ((Suppl 2)):112.
45. Rueda B, Orozco G, Raya E, et al. The IL23R Arg381Gln nonsynonymous polymorphism confers susceptibility to ankylosing spondylitis. Ann Rheum Dis 2008; 67:1451-1454.
46. Cui X, Hawari F, Alsaaty S, et al. Identification of ARTS-1 as a novel TNFR1-binding protein that promotes TNFR1 ectodomain shedding. J Clin Invest 2002; 110:515-526.
47. Cui X, Rouhani FN, Hawari F, Levine SJ. An aminopeptidase, ARTS-1, is required for interleukin-6 receptor shedding.J Biol Chem 2003; 278:28677-28685.
48. Cui X, Rouhani FN, Hawari F, Levine SJ. Shedding of the type II IL-1 decoy receptor requires a multifunctional aminopeptidase, aminopeptidase regulator of TNF receptor type 1 shedding. J Immunol 2003; 171:6814-6819.
49. Cepek KL, Shaw SK, Parker CM, et al. Adhesion between epithelial cells and T lymphocytes mediated by E-cadherin and the alpha E beta 7 integrin. Nature 1994; 372:190-193.
50. Elewaut D, De Keyser F, Van Den Bosch F, et al. Enrichment of Tcells carrying beta7 integrins in inflamed synovial tissue from patients with early spondy-loarthropathy, compared to rheumatoid arthritis. J Rheumatol 1998; 25:1932-1937.
51. Austrup F, Rebstock S, Kilshaw PJ, Hamann A. Transforming growth factor-beta 1-induced expression of the mucosa-related integrin alpha E on lymphocytes is not associated with mucosa-specific homing. Eur J Immunol 1995; 25:1487-1491.
52. Brew R, West DC, Burthem J, Christmas SE. Expression of the human mucosal lymphocyte antigen, HML-1, by T cells activated with mitogen or specific antigen in vitro. Scand J Immunol 1995; 41:553-562.
53. Baeten D, Demetter P, Cuvelier C, et al. Comparative study of the synovial histology in rheumatoid arthritis, spondyloarthropathy, and osteoarthritis: influence of disease duration and activity. Ann Rheum Dis 2000; 59:945-953.
54. Demetter P, De Vos M, Van Huysse JA, et al. Colon mucosa of patients both with spondyloarthritis and Crohn's disease is enriched with macrophages expressing the scavenger receptor CD163. Ann Rheum Dis 2005; 64:321-324.
55. Baeten D, Demetter P, Cuvelier CA, et al. Macrophages expressing the scavenger receptor CD163: a link between immune alterations of the gut and synovial inflammation in spondyloarthropathy. J Pathol 2002; 196:343-350.
56. Hacquard-Bouder C, Chimenti MS, Giquel B, et al. Alteration of antigen-independent immunologic synapse formation between dendritic cells from HLA-B27-transgenic rats and CD4\+ T cells: selective impairment of costi-mulatory molecule engagement by mature HLA-B27. Arthritis Rheum 2007; 56:1478-1489.
57. Hacquard-Bouder C, Falgarone G, Bosquet A, et al. Defective costimulatory function is a striking feature of antigen-presenting cells in an HLA-B27-transgenic rat model of spondylarthropathy. Arthritis Rheum 2004; 50:1624-1635.
58. Stagg AJ, Breban M, Hammer RE, et al. Defective dendritic cell (DC) function in a HLA-B27 transgenic rat model of spondyloarthropathy (SpA). Adv Exp Med Biol 1995; 378:557-559.
59. Fert I, Glatigny S, Poulain C, et al. Correlation between dendritic cell functional defect and spondylarthritis phenotypes in HLA-B27/HUMAN beta2-microglobulin-transgenic rat lines. Arthritis Rheum 2008; 58:3425-3429.
60. Dhaenens M, Fert I, Glatigny S, et al. Dendritic cells from spondylarthritis-prone HLA-B27-transgenic rats display altered cytoskeletal dynamics, class II major histocompatibility complex expression, and viability. Arthritis Rheum 2009; 60:2622-2632.
61. Weaver CT, Harrington LE, Mangan PR, et al. Th17: an effector CD4 T cell lineage with regulatory T cell ties. Immunity 2006; 24:677-688.
62. Amadi-Obi A, Yu CR, Liu X, et al. TH17 cells contribute to uveitis and scleritis and are expanded by IL-2 and inhibited by IL-27/STAT1. Nat Med 2007; 13:711-718.
63. Yen D, Cheung J, Scheerens H, et al. IL-23 is essential for T cell-mediated colitis and promotes inflammation via IL-17 and IL-6. J Clin Invest 2006; 116:1310-1316.
64. Aggarwal S, Ghilardi N, Xie MH, et al. Interleukin-23 promotes a distinct CD4 T cell activation state characterized by the production of interleukin-17. J Biol Chem 2003; 278:1910-1914.
65. Jandus C, Bioley G, Rivals JP, et al. Increased numbers of circulating polyfunctional Th17 memory cells in patients with seronegative spondylarthri-tides. Arthritis Rheum 2008; 58:2307-2317.
66. Wendling D, Cedoz JP, Racadot E, Dumoulin G. Serum IL-17, BMP-7, and bone turnover markers in patients with ankylosing spondylitis. Joint Bone Spine 2007; 74:304-305.
67. Melis L, Vandooren B, Kruithof E, Jacques P, De Vos M, Mielants H, et al. Systemic levels of IL-23 are strongly associated with disease activity in rheumatoid arthritis but not spondyloarthritis. Ann Rheum Dis 2010; 69: 618-623
68. Krzysiek R, Lefevre EA, Bernard J, et al. Regulation of CCR6 chemokine receptor expression and responsiveness to macrophage inflammatory pro-tein-3alpha/CCL20 in human B cells. Blood 2000; 96:2338-2345.
69. Ciccia F, Bombardieri M, Principato A, et al. Overexpression of interleukin-23, but not interleukin-17, as an immunologic signature of subclinical intestinal inflammation in ankylosing spondylitis. Arthritis Rheum 2009; 60:955-965.
70. DeLay ML, Turner MJ, Klenk EI, et al. HLA-B27 misfolding and the unfolded protein response augment interleukin-23 production and are associated with Th17 activation in transgenic rats. Arthritis Rheum 2009; 60:2633-2643.
71. Apostolaki M, Manoloukos M, Roulis M, et al. Role of beta7 integrin and the chemokine/chemokine receptor pair CCL25/CCR9 in modeled TNF-dependent Crohn's disease. Gastroenterology 2008; 134:2025-2035.
72. Jacques P, Venken K, Van Beneden K, Hammad H, Seeuws S, Drennan M, et al. Invariant Natural Killer T Cells Are Natural Regulators of Inflammation in Murine Spondylarthritis. Arthritis Rheum 2010; 62:988-999.
73. Davis JC Jr, Van Der Heijde D, Braun J, et al. Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: a randomized, controlled trial. Arthritis Rheum 2003; 48:3230-3236.
74. De Keyser F, Baeten D, Van den Bosch F, et al. Gut inflammation and spondyloarthropathies. Curr Rheumatol Rep 2002; 4:525-532.
75. D'Haens G, Swijsen C, Noman M, et al. Etanercept in the treatment of active refractory Crohn's disease: a single-center pilot trial. Am J Gastroenterol 2001; 96:2564-2568.
76. Sandborn WJ, Hanauer SB, Katz S, et al. Etanercept for active Crohn's disease: a randomized, double-blind, placebo-controlled trial. Gastroenterol-ogy 2001; 121:1088-1094.
77. Doubremelle M, Bourreille A, Zerbib F, et al. Treatment of Crohn's disease with anti-TNF alpha antibodies (infliximab): results of a multicentric and retrospective study. Gastroenterol Clin Biol 2002; 26:973-979.
78. Sandborn WJ, Hanauer S, Loftus EV Jr, et al. An open-label study of the human anti-TNF monoclonal antibody adalimumab in subjects with prior loss of response or intolerance to infliximab for Crohn's disease. Am J Gastro-enterol 2004; 99:1984-1989.
79. Youdim A, Vasiliauskas EA, Targan SR, et al. A pilot study of adalimumab in infliximab-allergic patients. Inflamm Bowel Dis 2004; 10:333-338.
80. Braun J, Baraliakos X, Listing J, et al. Differences in the incidence of flares or new onset of inflammatory bowel diseases in patients with ankylosing spon-dylitis exposed to therapy with antitumor necrosis factor alpha agents. Arthritis Rheum 2007; 57:639-647.
81. Haibel H, Rudwaleit M, Brandt HC, et al. Adalimumab reduces spinal symptoms in active ankylosing spondylitis: clinical and magnetic resonance imaging results of a fifty-two-week open-label trial. Arthritis Rheum 2006; 54:678-681.
82. van der Heijde D, Kivitz A, Schiff MH, et al. Efficacy and safety of adalimumab in patients with ankylosing spondylitis: results of a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2006; 54:2136-2146.
83. Gottlieb A, Menter A, Mendelsohn A, et al. Ustekinumab, a human interleukin 12/23 monoclonal antibody, for psoriatic arthritis: randomised, double-blind, placebo-controlled, crossover trial. Lancet 2009; 373:633-640.
84. Sandborn WJ, Feagan BG, Fedorak RN, et al. A randomized trial of Usteki-numab, a human interleukin-12/23 monoclonal antibody, in patients with moderate-to-severe Crohn's disease. Gastroenterology 2008; 135:1130-1141.
85. Schreiber S, Rutgeerts P, Fedorak RN, et al. A randomized, placebo-controlled trial of certolizumab pegol (CDP870) for treatment of Crohn's disease. Gastroenterology 2005; 129:807-818.
86. Jacques P, Elewaut D. Joint expedition: linking gut inflammation to arthritis. Mucosal Immunol 2008; 1:364-371.